Join Us

We are 219,660 members in 84 forums discussing 161,620 topics.

Help with Abbreviations

Topic: Did anybody else see this?

Forum: Stage IV/Metastatic Breast Cancer ONLY —

Please respect that this forum is for members with stage IV/metastatic breast cancer only. There is a separate forum for caregivers and friends: Caring for Someone with Stage 4 or Mets.

Metastatic breast cancer (MBC; also called stage IV) is breast cancer that has spread to other parts of the body, most commonly the bones, liver, brain, or lungs. Metastatic breast cancer can be treated but not cured. Metastatic disease is NOT hopeless. There are a wide variety of treatment options for metastatic breast cancer, and new medicines are being tested every day. More and more people are living life to the fullest while being treated for metastatic breast cancer.

Note: Please contact your doctor for any specific concerns about symptoms you are experiencing or your course of treatment.

Learn more about living with MBC.

Intro medically reviewed by: Brian Wojciechowski, M.D.
Last review date: November 22, 2020

Posted on: Jun 15, 2013 07:02PM - edited Jun 15, 2013 08:18PM by Moderators

sincitydealer wrote:

I just saw an interview with somebody from Duke University on Fox news.  He made it sound like this is the Holy Grail for estrogen positive women who've failed on Tamoxifin and Aromatase Inhibitors.  I sure hope he's right!  This has been approved in Europe and will most likely be approved here.  He said it was right under their noses all along, and it's expected to work well on late stage breast cancer.  This would be the next step after failure of the anti-hormonals instead of going on to chemo.  It completely shuts down the estrogen receptors.  Some of you may qualify for the trial.

Osteoporosis Drug Stops Growth of Breast Cancer Cells, Even in Resistant Tumors

About This Article

Article Details

Published: June 15, 2013
Updated: June 15, 2013

By Duke Medicine News and Communications

DURHAM, N.C. -- A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute study.

The findings, presented June 15, 2013, at the annual Endocrine Society meeting in San Francisco, indicate that the drug bazedoxifene packs a powerful one-two punch that not only prevents estrogen from fueling breast cancer cell growth, but also flags the estrogen receptor for destruction.

"We found bazedoxifene binds to the estrogen receptor and interferes with its activity, but the surprising thing we then found was that it also degrades the receptor; it gets rid of it," said senior author Donald McDonnell, PhD, chair of Duke's Department of Pharmacology and Cancer Biology.

In animal and cell culture studies, the drug inhibited growth both in estrogen-dependent breast cancer cells and in cells that had developed resistance to the anti-estrogen tamoxifen and/or to the aromatase inhibitors, two of the most widely used types of drugs to prevent and treat estrogen-dependent breast cancer. Currently, if breast cancer cells develop resistance to these therapies, patients are usually treated with toxic chemotherapy agents that have significant side effects.

Bazedoxifene is a pill that, like tamoxifen, belongs to a class of drugs known as specific estrogen receptor modulators (SERMs). These drugs are distinguished by their ability to behave like estrogen in some tissues, while significantly blocking estrogen action in other tissues. But unlike tamoxifen, bazedoxifene has some of the properties of a newer group of drugs, known as selective estrogen receptor degraders, or SERDs, which can target the estrogen receptor for destruction.

"Because the drug is removing the estrogen receptor as a target by degradation, it is less likely the cancer cell can develop a resistance mechanism because you are removing the target," said lead author Suzanne Wardell, PhD, a research scientist working in McDonnell's lab.

Many investigators had assumed that once breast cancer cells developed resistance to tamoxifen, they would be resistant to all drugs that target the estrogen receptor, McDonnell explained.

"We discovered that the estrogen receptor is still a good target, even after it resistance to tamoxifen has developed," he said.

The investigators tested a variety of breast cancer cell types, including tamoxifen-sensitive cells that are resistant to the drug lapatinib, another targeted therapy that is used to treat patients with advanced breast cancer whose tumors contain the mutant HER2 gene. These cells had previously been shown to reactivate estrogen signaling in order to acquire drug resistance. In this cell type, bazedoxifene also potently inhibited cell growth.

Paradoxically, in bone tissue, bazedoxifene mimics the action of estrogen, helping protect it from destruction. Because bazedoxifene has already undergone safety and efficacy studies as a treatment for osteoporosis, it may be a viable near-term option for patients with advanced breast cancer whose tumors have become resistant to other treatment options, Wardell reported. In clinical trials, the most often reported side effect was hot flashes in the bazedoxifene treatment groups.

The study was funded by a research grant from Pfizer Pharmaceuticals, maker of bazedoxifene.

In addition to Wardell and McDonnell, Erik Nelson and Christina Chao of the Department of Pharmacology and Cancer Biology, Duke University School of Medicine, contributed to the research.

Edited by Mods to tidy up imported formatting

Log in to post a reply

Page 6 of 6 (152 results)

Posts 151 - 152 (152 total)

Log in to post a reply

May 22, 2015 05:52AM TarheelMichelle wrote:

This is great news for me. I am thrilled to hear this. I have followed your posts, but was on Tamox and was not having progression. That changed. Now I'm struggling to stay on Afinitor, (combined with Tamox) and if the third time isn't a charm, I'm going to ask my doctor about this. As a NC resident and native, I'm proud of the research coming out of Duke. I'm grateful for ANY breast cancer research that can keep me alive longer and preserve my quality of life. Thank you for your research work and for sharing not only information, but encouragement.

Ronda - Extensive mets to lungs & bones. My life is Stage IV precious. Celebrating 8 years with Stage IV 12/2019 Dx 2/14/2008, IDC, Left, 1cm, Stage IA, Grade 2, 0/3 nodes, ER+/PR+, HER2- Surgery 3/11/2008 Lumpectomy: Left; Lymph node removal: Left, Sentinel Radiation Therapy 4/17/2008 Dx 12/19/2011, Stage IV, metastasized to bone/lungs, mets, ER+/PR+, HER2- Hormonal Therapy 1/31/2012 Aromasin (exemestane) Hormonal Therapy 12/19/2012 Faslodex (fulvestrant) Hormonal Therapy 7/16/2013 Tamoxifen pills (Nolvadex, Apo-Tamox, Tamofen, Tamone) Surgery 4/24/2014 Reconstruction (left) Radiation Therapy 11/21/2014 External: Bone Targeted Therapy 11/17/2015 Afinitor (everolimus) Targeted Therapy 5/20/2016 Hormonal Therapy 6/1/2016 Femara (letrozole) Targeted Therapy Ibrance (palbociclib) Hormonal Therapy Faslodex (fulvestrant)
Log in to post a reply

May 23, 2015 03:23PM WannaCruize wrote:

Thanks so much Dr. Wardell, it is very exciting news. I've been watching for news on this otential treatment for my daughter, diagnosed with Stage IV IBC 2.5 years ago at age 32. She had been stable on hormonals for about a year, but has now had progression to her liver, and is back on chemo with mixed results. We will be bringing this up to her Onc at our appointment next week to review her latest scans.

Diagnosed with Stage 1 IDC in January 2016, just 2 months after my daughter lost her 3 year battle with Stage IV IBC. Dx 1/22/2016, IDC, Left, 1cm, Stage IA, Grade 3, 0/1 nodes, ER-/PR-, HER2- Surgery 2/11/2016 Mastectomy: Left, Right Chemotherapy 3/9/2016 Cytoxan (cyclophosphamide), Taxotere (docetaxel)

Page 6 of 6 (152 results)